Valvular & structural heart disease
Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement: Results From the CHOICE-MI Registry
Authors' conclusion
TMVR using dedicated TF devices demonstrates favorable safety, durable MR reduction, and sustained functional improvement in high-risk patients.
Study context
- Population
- Patients with mitral regurgitation (MR) undergoing transfemoral (TF) transcatheter mitral valve replacement (TMVR) with dedicated devices (CHOICE-MI Registry)9 different devices
- Participants
- 124 patients
- Outcome
- All-cause mortality or HF hospitalization
- Follow-up
- Up to 2 years
Methodological detailsinternational, multicentre (41 centres)
- International
- Multicentre (41 centres)
Main finding
As reported in the abstract
Primary endpoint rate at 2 years
52.4%
95% CI 40.2%–62.1%
Observational data: associations, not effects.
Further findings
All-cause mortality or HF hospitalization · 1 year
- Primary endpoint rate at 1 year
- 44.1% (95% CI: 30.6%-50.0%)
CV mortality · 1 and 2 years
- CV mortality at 1 year
- 14.7% (95% CI: 7.9%-21.5%)
- CV mortality at 2 years
- 20.3% (95% CI: 11.4%-29.1%)
Technical success
- Technical success
- 113 of 124 patients (91.1%)
Residual MR ≤1+ · discharge
- Residual MR ≤1+ at discharge, stable at follow-up
- 94.9%
NYHA functional class · 1 and 2 years
- NYHA class significantly improved at 1- and 2-year follow-up
Predictors
- AF independent predictor of the primary endpoint; technical success associated with survival
Original publication
Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement: Results From the CHOICE-MI Registry. JACC Cardiovasc Interv. Published 20 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →